{
  "input": {
    "mode": "build_chain",
    "query": {
      "entity": "Atypical haemolytic uraemic syndrome",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_ravulizumab",
          "name": "Ravulizumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_avacopan",
          "name": "Avacopan"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_c5_inhibitor",
          "name": "C5 Inhibitor"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_corticosteroids",
          "name": "Corticosteroids"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_plasmapheresis",
          "name": "Plasmapheresis"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_rituximab",
          "name": "Rituximab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_mycophenolate_mofetil",
          "name": "Mycophenolate mofetil"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_tacrolimus",
          "name": "Tacrolimus"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_complement_inhibitors",
          "name": "Complement inhibitors"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_eltrombopag",
          "name": "Eltrombopag"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 4
    },
    "constraints": {
      "require_disjoint_paths": 2,
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "drug_eculizumab",
          "type": "Drug",
          "label": "Eculizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ravulizumab",
          "type": "Drug",
          "label": "Ravulizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_avacopan",
          "type": "Drug",
          "label": "Avacopan",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_c5_inhibitor",
          "type": "Drug",
          "label": "C5 Inhibitor",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_corticosteroids",
          "type": "Drug",
          "label": "Corticosteroids",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_plasmapheresis",
          "type": "Drug",
          "label": "Plasmapheresis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_rituximab",
          "type": "Drug",
          "label": "Rituximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_mycophenolate_mofetil",
          "type": "Drug",
          "label": "Mycophenolate mofetil",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tacrolimus",
          "type": "Drug",
          "label": "Tacrolimus",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_complement_inhibitors",
          "type": "Drug",
          "label": "Complement inhibitors",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_eltrombopag",
          "type": "Drug",
          "label": "Eltrombopag",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_a_h_u_s",
          "type": "Disease",
          "label": "Atypical haemolytic uraemic syndrome",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_eculizumab",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "已知炎症及补体抑制作用于此病"
        },
        {
          "source": "drug_ravulizumab",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "与Eculizumab相似的补体抑制机制"
        },
        {
          "source": "drug_avacopan",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "调节补体途径，针对该疾病的理论基础"
        },
        {
          "source": "drug_c5_inhibitor",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接靶向补体系统"
        },
        {
          "source": "drug_corticosteroids",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "类固醇在控制炎症中常用"
        },
        {
          "source": "drug_plasmapheresis",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "清除血液中的有害成分"
        },
        {
          "source": "drug_cyclosporine",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "在免疫调节中应用"
        },
        {
          "source": "drug_rituximab",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "抗B细胞疗法可影响疾病过程"
        },
        {
          "source": "drug_mycophenolate_mofetil",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "用于控制免疫反应的药物"
        },
        {
          "source": "drug_tacrolimus",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "免疫抑制剂用于慢性病"
        },
        {
          "source": "drug_complement_inhibitors",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "补体抑制剂与疾病相关"
        },
        {
          "source": "drug_eltrombopag",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.45,
          "agent": "Proponent",
          "rationale": "理论上支持输血相关问题的管理"
        }
      ]
    },
    "subconclusions": [
      {
        "id": "C1",
        "text": "多种药物通过独立机制影响Atypical haemolytic uraemic syndrome",
        "confidence": "high"
      }
    ],
    "assumptions": [
      "药物具备到达作用靶点的能力（常识判断）"
    ],
    "uncertainties": [
      "某些药物的疗效及长期安全性需进一步验证"
    ],
    "next_focus_for_pi": [
      "是否需要更详细的作用机制及更多临床数据支持?"
    ]
  }
}